Canada’s regulatory approach to drugs for rare diseases: orphan drugs

Canada’s regulatory approach to drugs for rare diseases: orphan drugs Canada's regulatory approach: Drugs for rare diseases are authorized for sale in Canada under the Food and Drugs Act and Part C of the Food and Drug Regulations. 2023-12-02 Health Canada open-ouvert@tbs-sct.gc.ca Health and SafetyCanada’s regulatory approachdrugs for rare-diseasesorphan drugs Canada’s regulatory approach to drugs for rare diseases: orphan drugsHTML https://www.canada.ca/en/health-canada/services/licences-authorizations-registrations-drug-health-products/regulatory-approach-drugs-rare-diseases.html Canada’s regulatory approach to drugs for rare diseases: orphan drugsHTML https://www.canada.ca/fr/sante-canada/services/licences-autorisation-et-enregistrement-medicaments-et-produits-sante/approche-canada-reglementation-medicaments-maladies-rares.html

Canada's regulatory approach: Drugs for rare diseases are authorized for sale in Canada under the Food and Drugs Act and Part C of the Food and Drug Regulations.

Data and Resources

Similar records